Johnson & Johnson (JNJ) Getting Positive Media Coverage, Report Shows

Press coverage about Johnson & Johnson (NYSE:JNJ) has been trending positive on Saturday, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than 6,000 news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson earned a media sentiment score of 2.54 on their scale. InfoTrie also assigned press coverage about the company an news buzz score of 4 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media headlines that may have effected Johnson & Johnson’s analysis:

JNJ has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Tuesday, November 20th. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, October 14th. Citigroup boosted their price objective on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a report on Monday, October 22nd. Finally, Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a report on Friday, September 14th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $143.90.

NYSE:JNJ opened at $145.43 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.99. The company has a market capitalization of $391.46 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 2.28 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The firm’s revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts forecast that Johnson & Johnson will post 8.16 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

In other Johnson & Johnson news, CEO Alex Gorsky sold 264,465 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $145.96, for a total value of $38,601,311.40. Following the completion of the sale, the chief executive officer now owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Peter Fasolo sold 166,695 shares of the business’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $146.41, for a total transaction of $24,405,814.95. Following the sale, the vice president now directly owns 155,540 shares of the company’s stock, valued at approximately $22,772,611.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 510,544 shares of company stock valued at $74,414,877. 0.22% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/12/08/johnson-johnson-jnj-getting-positive-media-coverage-report-shows.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading: Asset Allocation and Your Retirement

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply